Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL092 + atezolizumab vs regorafenib in metastatic colorectal cancer
2021-003243-21Phase 3Active
- Sponsor
- Exelixis, Inc.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing XL092 + atezolizumab with Regorafenib (2 arms). Primary endpoint: Overall survival. Started Jul 2022; status: active.
02
Drugs
zanzalintinibatezolizumabregorafenib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2021-003243-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003243-21.